Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 2

3(60.0%)

Phase 3

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 2(3)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03590171Phase 2Recruiting

International Study for Treatment of High Risk Childhood Relapsed ALL 2010

Role: collaborator

NCT06208657Phase 1Recruiting

Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer

Role: lead

NCT04897880Phase 2Terminated

A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT

Role: lead

NCT05504772Recruiting

Precision Medicine for Every Child With Cancer

Role: lead

NCT03336931Active Not Recruiting

PRecISion Medicine for Children With Cancer

Role: collaborator

NCT01802814Phase 3Completed

International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010

Role: collaborator

NCT01949129Phase 2Recruiting

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Role: collaborator

All 7 trials loaded